Previous 10 | Next 10 |
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resis...
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab ; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial response NT219 exposure at the highest dose level reaching human equi...
2023-09-27 09:59:57 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resi...
2023-08-22 13:16:23 ET Purple Biotech press release ( NASDAQ: PPBT ): Q2 GAAP EPS of -$0.25. Research and Development Expenses were $3.7 million, an increase of $1.7 million or 85%, compared to $2 million in the same period of 2022. Adjusted net loss for the three mont...
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway extended into H1 2025 REHOVOT, Israel, Aug. 22, 2023 (GLOBE NEWSWIRE) ...
2023-07-12 08:16:40 ET ShiftPixy ( PIXY ) -33% on pricing of $3.1 Million public Offering . Silk Road Medical ( SILK ) -23%. PainReform ( PRFX ) -24% . WANG & LEE GROUP ( WLGS ) -10% . NanoViricides ( NNVC ) -8% . CytoMed...
2023-07-11 15:02:45 ET Israeli drug developer Purple Biotech ( NASDAQ: PPBT ) reported encouraging Phase 1 data for its immuno-oncology therapy CM24 in the treatment of advanced pancreatic cancer, with initial results from a Phase 2 study expected by the end of 2023. Purple said...
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3 rd line PDAC patients Randomized Phase 2 study is enrolling as expected with initial Phase 2 data expected by the end of 2023 REHOVOT, Israel, July 11, 20...
2023-05-16 16:43:08 ET Purple Biotech press release ( NASDAQ: PPBT ): Q1 GAAP EPS of -$0.25 beats by $0.12 . For further details see: Purple Biotech GAAP EPS of -$0.25 beats by $0.12
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Purple Biotech Ltd ADR (Sponsored) Level 3 Website:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...